ESPR
NASDAQ · Pharmaceuticals
Esperion Therapeutics Inc
$3.15
-0.02 (-0.63%)
Financial Highlights (FY 2026)
Revenue
499.77M
Net Income
-28,114,342
Gross Margin
67.9%
Profit Margin
-5.6%
Rev Growth
+74.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 67.9% | 68.0% | 30.4% | 30.4% |
| Operating Margin | 14.9% | 13.5% | 33.0% | 36.5% |
| Profit Margin | -5.6% | -5.4% | 30.0% | 30.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 499.77M | 285.94M | 122.60M | 119.77M |
| Gross Profit | 339.59M | 194.30M | 37.28M | 36.42M |
| Operating Income | 74.72M | 38.47M | 40.47M | 43.73M |
| Net Income | -28,114,342 | -14,477,004 | 36.77M | 36.24M |
| Gross Margin | 67.9% | 68.0% | 30.4% | 30.4% |
| Operating Margin | 14.9% | 13.5% | 33.0% | 36.5% |
| Profit Margin | -5.6% | -5.4% | 30.0% | 30.3% |
| Rev Growth | +74.8% | +74.8% | -8.9% | +18.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 272.00M | 279.82M |
| Total Equity | — | — | 501.71M | 541.43M |
| D/E Ratio | — | — | 0.54 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 74.86M | 40.69M | 61.92M | 62.84M |
| Free Cash Flow | — | — | 30.39M | 39.08M |